Core Insights - VitalHub Corp. achieved significant financial growth in 2025, surpassing $100 million in total revenue, with a 59% year-over-year increase [3][7] - The company reported an Annual Recurring Revenue (ARR) of $96.1 million, reflecting a 35% increase year-over-year [1][4] - Adjusted EBITDA rose by 49% year-over-year to $26.6 million, representing 24% of total revenue [7][16] Financial Performance - Total revenue for Q4 2025 was $31.4 million, a 52% increase from $20.6 million in Q4 2024 [6][7] - Gross profit margin was 79% in Q4 2025, slightly down from 81% in the same period last year [7][8] - Net income for Q4 2025 was $4.1 million, compared to $787,244 in Q4 2024, marking a 417% increase [7][15] Growth Drivers - The company experienced organic growth of $7.2 million or 10% in 2025, alongside acquisition growth of $15.9 million or 22% [7][8] - VitalHub's strategic acquisitions have filled gaps in its portfolio, enhancing cross-selling opportunities globally [3][10] - The company is leveraging AI in its product roadmap to optimize operations and improve productivity [3] Balance Sheet Strength - As of December 31, 2025, VitalHub had cash and short-term investments of $119.2 million, up from $56.6 million a year earlier [9] - Deferred revenue increased to $45.4 million from $35.6 million, indicating strong future revenue potential [9] Market Position - VitalHub serves over 1,300 clients globally, focusing on health and human services with a comprehensive product suite [10] - The company is headquartered in Toronto and employs over 700 staff worldwide, with a dedicated innovation lab in Sri Lanka [10]

Core Viewpoint - VitalHub Corp. has announced a change in the release date for its financial results for Q4 and the year ended December 31, 2025, now scheduled for March 18, 2026, after market close [1][2] Group 1: Financial Results Announcement - The financial results will be released on March 18, 2026, after market close [2] - A conference call to discuss the results is scheduled for March 19, 2026, at 8:00 am EST [2] - The change in timing is due to the need for additional time to finalize the annual financial statements [2] Group 2: Company Overview - VitalHub is a leading software company focused on empowering health and human services providers globally [2] - The company offers a comprehensive product suite that includes electronic health records, operational intelligence, and workforce automation solutions, serving over 1,300 clients across the UK, Canada, and other regions [2] - VitalHub has a two-pronged growth strategy that includes targeting organic opportunities within its product suite and pursuing an aggressive M&A plan [2] - The company is headquartered in Toronto and employs over 700 individuals globally, with a VitalHub Innovations Lab located in Sri Lanka [2]

DALLAS, TEXAS . . March 10, 2026. Valhi, Inc. (NYSE: VHI) reported a net loss attributable to Valhi stockholders of $53.2 million, or $1.86 per share, in the fourth quarter of 2025 compared to net income of $22.8 million, or $.80 per share, in the fourth quarter of 2024. For the full year of 2025, Valhi reported a net loss attributable to Valhi stockholders of $57.6 million, or $2.02 per share, compared to net income of $108.0 million, or $3.79 per share, for the full year of 2024. Net income attributable t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-5467 VALHI, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of Incorporation or organization) Delaware 87 ...

Core Viewpoint - Valhi, Inc. reported significant financial losses in 2025, primarily driven by poor performance in its Chemicals Segment, which faced lower TiO2 selling prices and increased production costs [1][4][3]. Financial Performance - In Q4 2025, Valhi recorded a net loss of $53.2 million ($1.86 per share), a stark contrast to a net income of $22.8 million ($0.80 per share) in Q4 2024 [1]. - For the full year 2025, the net loss attributable to Valhi stockholders was $57.6 million ($2.02 per share), compared to a net income of $108.0 million ($3.79 per share) in 2024 [1]. - The Chemicals Segment's net sales were $418.3 million in Q4 2025, down 1% from $423.1 million in Q4 2024, and $1.9 billion for the full year 2025, also down 1% from $1.887 billion in 2024 [3][14]. Chemicals Segment Analysis - The Chemicals Segment's operating loss in Q4 2025 was $60.1 million, compared to an operating income of $32.6 million in Q4 2024 [4]. - For the full year 2025, the operating loss was $24.5 million, down from an operating income of $138.5 million in 2024 [4]. - Average TiO2 selling prices decreased by 10% from the beginning of 2025, with Q4 prices being 8% lower than Q4 2024 [3][4]. Component Products Segment - The Component Products Segment reported net sales of $37.7 million in Q4 2025, slightly down from $38.4 million in Q4 2024, but increased for the full year to $158.3 million from $145.9 million in 2024 [6][14]. - Operating income for this segment was $5.6 million in Q4 2025, up from $4.9 million in Q4 2024, and $22.6 million for the full year, compared to $17.0 million in 2024 [6][14]. Real Estate Management and Development Segment - This segment achieved net sales of $38.5 million in Q4 2025, up from $19.4 million in Q4 2024, but full-year sales decreased to $59.3 million from $71.8 million in 2024 [7][14]. - The segment recognized tax increment infrastructure reimbursements of $34.2 million in 2025, compared to $30.3 million in 2024 [7]. Corporate Expenses and Other Financial Metrics - Corporate expenses in 2025 were comparable to 2024, with interest income and other decreasing by $1.4 million in Q4 and $5.4 million for the full year [8]. - Interest expense increased by $1.9 million in Q4 2025 and $7.2 million for the full year, attributed to higher average debt balances and interest rates [8].

TORONTO, March 09, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today that Novari Health (“Novari”), a VitalHub company, and Niagara Health are building upon an existing partnership by implementing Novari’s Medical Imaging Requisition Management (“MIRM”) and eRequest referral management technologies across the Niagara Region. Novari’s MIRM and eRequest technologies will be implemented at all of Niagara Health’s sites including Fort Erie Complex and ...

Group 1 - VitalHub Corp. will release its financial results for Q4 2025 on March 12, 2026, after market close [1] - A conference call will be held on March 13, 2026, at 9:00 am EST, hosted by CEO Dan Matlow and CFO Brian Goffenberg [1] - The company serves over 1,000 clients globally, focusing on health and human services [2] Group 2 - VitalHub has a two-pronged growth strategy that includes organic growth within its product suite and an aggressive M&A plan [2] - The company is headquartered in Toronto and has over 500 employees worldwide, including a VitalHub Innovations Lab in Sri Lanka [2]

Core Viewpoint - Valhi, Inc. is set to announce its fourth quarter 2025 earnings on March 10, 2026, after market close, pending year-end closing procedures [1] Group 1: Company Overview - Valhi, Inc. operates in multiple industries including chemicals (specifically TiO2), component products (such as security products and recreational marine components), and real estate management and development [1] Group 2: Financial Reporting - The company will release its earnings report for the fourth quarter of 2025 on March 10, 2026, after the market closes [1]

Group 1 - Valhi, Inc. (VHI) is facing challenges due to lower TiO2 prices, which significantly impact its business despite a positive effect from consolidating a business after a joint venture buyout [2] - The Valkyrie Trading Society is a team of analysts focused on high conviction and obscure developed market ideas, aiming for downside-limited investments that can generate non-correlated and outsized returns in the current economic environment [2] - The Value Lab offers a portfolio with real-time updates, 24/7 chat support, regular global market news reports, feedback on member stock ideas, new trades monthly, quarterly earnings write-ups, and daily macro opinions [2]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Shoulder Innovations, Inc. (SI) is up 14% at $13.01 [3] - BILL Holdings, Inc. (BILL) is up 11% at $52.14 [3] - On Holding AG (ONON) is up 8% at $38.24 [3] - CuriosityStream Inc. (CURI) is up 8% at $4.08 [3] - Clearwater Analytics Holdings, Inc. (CWAN) is up 7% at $19.80 [3] - Valhi, Inc. (VHI) is up 7% at $14.54 [3] - Beam Global (BEEM) is up 7% at $2.29 [3] - FGI Industries Ltd. (FGI) is up 6% at $5.66 [3] - The Honest Company, Inc. (HNST) is up 6% at $2.68 [3] - China Automotive Systems, Inc. (CAAS) is up 5% at $4.40 [3] Premarket Losers - Graphjet Technology (GTI) is down 22% at $3.02 [4] - Black Rock Coffee Bar, Inc. (BRCB) is down 10% at $21.90 [4] - Rain Enhancement Technologies Holdco, Inc. (RAIN) is down 9% at $4.90 [4] - Stereotaxis, Inc. (STXS) is down 9% at $2.59 [4] - Biohaven Ltd. (BHVN) is down 8% at $7.82 [4] - Epsium Enterprise Limited (EPSM) is down 7% at $3.15 [4] - Cycurion, Inc. (CYCU) is down 7% at $3.13 [4] - Galecto, Inc. (GLTO) is down 6% at $22.09 [4] - Anbio Biotechnology (NNNN) is down 6% at $21.68 [4] - Ridgetech, Inc. (RDGT) is down 5% at $3.46 [4]